Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria (BactHub)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04065750|
Recruitment Status : Not yet recruiting
First Posted : August 22, 2019
Last Update Posted : August 22, 2019
The primary objective of the study is to identify the risk factors of community-acquired bacteremia to resistant bacteria.
As the secondary objectives, the study aims
- to describe the episodes of epidemiology of bacteremia (community-acquired and nosocomial) with inpatient patients in APHP.
- to research a potential correlation between the incidence of community-acquired bacteremia of studied germs and the evolution of antibiotics consumption in general population in Île de France region.
- to distinguish three categories of community-acquired bacteremia: real community-acquired infections, infections beginning in community (patients discharged a community care center within 3 months), the nosocomial infections (patients discharged a health center within 7 jours). Describe the epidemiology of resistance and the differential impact of individual exposure to antibiotics in these three categories.
- to identify, according to pathogens, a temporal threshold from which a prior stay in a health center or HAD would impact on the occurrence of a community-acquired bacteremia with a resistant bacterium.
- to describe prospectively for follow-up of 1 year for hospitalized patients for a community-acquired or nosocomial bacteremia: mortality at one month and 3 months, re-hospitalization for an infectious episode and isolated bacteria during this later episode.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||45000 participants|
|Official Title:||Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria|
|Estimated Study Start Date :||November 2019|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
- Incidence of bacteraemia [ Time Frame: through study completion, an average of 3 months ]
- Mortality [ Time Frame: at 30 day and 90 day ]Events of death will be recorded, the mortality rate will be calculated for 30 day and 90 day.
- Rehospitalization [ Time Frame: 12 months ]The rate of 12 months unplanned rehospitalization for infection by the same biological pathogenes was recorded.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04065750
|Contact: Laurence Watier, PhD||+33 (0) 1 45 68 83 01||Laurence.email@example.com|
|Contact: Salam Abbara, MD, PhD|
|Study Director:||Laurence Watier, PhD||INSERM / Institut Pasteur|
|Principal Investigator:||Didier Guillemont, MD, PhD||APHP, Université de Versailles Saint-Quentin-en-Yvelines|